Tramadol Krka Forðatafla 100 mg İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

tramadol krka forðatafla 100 mg

krka, d.d., novo mesto - tramadolum hýdróklóríð - forðatafla - 100 mg

Tramadol Krka Forðatafla 150 mg İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

tramadol krka forðatafla 150 mg

krka, d.d., novo mesto - tramadolum hýdróklóríð - forðatafla - 150 mg

Venlafaxin Medical Valley Forðatafla 225 mg İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

venlafaxin medical valley forðatafla 225 mg

medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 225 mg

Tibsovo Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Lyfnua Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

lyfnua

merck sharp & dohme b.v. - gefapixant - cough - hósti og kuldablöndur - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

Jaypirca Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - eitilfrumukrabbamein, mantle-cell - prótín nt-hemlar - treatment of mantle cell lymphoma (mcl).

Adcirca (previously Tadalafil Lilly) Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

adcirca (previously tadalafil lilly)

eli lilly nederland b.v. - tadalafil - háþrýstingur, lungnabólga - Þvaglát - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.